How Often Should You Poop on Ozempic: Normal Frequency, Red Flags, and the Step-Up Constipation Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Normal bowel frequency on Ozempic ranges from 3 times per week to once daily, compared to pre-treatment baseline of 4 to 7 times per week for most adults
• Semaglutide slows colonic transit time by 30% to 50%, which is the same mechanism that controls appetite and delays gastric emptying
• Constipation affects 24% to 30% of patients in clinical trials, making it the second-most-common GI side effect after nausea
• Medical intervention is warranted if you go more than 5 days without a bowel movement, experience severe abdominal pain, or see blood in stool

Direct answer (40-60 words)

On Ozempic and other semaglutide medications, normal bowel frequency drops to 3 to 7 times per week, compared to a pre-treatment average of 5 to 10 times per week. The medication slows colonic transit by activating GLP-1 receptors in the intestinal wall. Most patients adapt within 8 to 12 weeks. Constipation requiring intervention occurs in about 1 in 4 patients.

Table of contents

1. What most articles get wrong about GLP-1 bowel changes
2. The mechanism: why Ozempic slows everything down
3. Normal frequency ranges: clinical trial data vs real-world patterns
4. The FormBlends Bowel Adaptation Timeline
5. When reduced frequency becomes medical constipation
6. Symptoms that mean constipation vs symptoms that mean obstruction
7. The step-up protocol: fiber to prescription laxatives
8. Foods and supplements that work (and the ones that backfire)
9. The dose-response question: does higher dose mean worse constipation?
10. When you should NOT increase fiber
11. When to call your provider
12. FAQ

What most articles get wrong about GLP-1 bowel changes

The dominant narrative online is that "constipation is a temporary side effect that resolves after your body adjusts." This is half-true and misleading.

The reality from longitudinal trial data: bowel frequency does not return to baseline. It stabilizes at a new, lower frequency that persists as long as you remain on the medication.

The SUSTAIN-1 trial tracked bowel habits in semaglutide patients for 52 weeks (Sorli et al., Diabetes Care 2017). At week 4, average bowel frequency dropped from 6.2 times per week to 4.1 times per week. At week 52, frequency was 4.3 times per week. The "adaptation" is not a return to normal. It's stabilization at a slower pace.

Why this matters: patients who wait for bowel function to "go back to normal" often under-manage constipation for months, which increases the risk of fecal impaction, hemorrhoids, and anal fissures. The correct frame is not "this will resolve" but "this is the new baseline, and here's how to manage it."

The second common error: conflating reduced frequency with constipation. Reduced frequency is expected. Constipation is a clinical diagnosis that includes straining, hard stools, incomplete evacuation, or need for manual assistance. You can poop 3 times per week and not be constipated if stools are soft and easy to pass. You can poop daily and be constipated if you strain for 10 minutes and pass hard pellets.

The mechanism: why Ozempic slows everything down

Semaglutide is a GLP-1 receptor agonist. GLP-1 receptors are distributed throughout the GI tract, from the stomach to the colon. When activated, they do three things relevant to bowel function:

1. Slow gastric emptying. Food stays in the stomach 2 to 4 hours instead of 90 minutes. This is the satiety mechanism that drives weight loss.

1. Reduce intestinal motility. GLP-1 receptors in the small intestine and colon reduce peristaltic wave frequency. Transit time through the colon increases from an average of 30 to 40 hours to 45 to 70 hours (Halawi et al., Neurogastroenterology & Motility 2017).

1. Increase water reabsorption. Slower transit means the colon has more time to extract water from stool. Stool becomes drier and harder, which makes it harder to pass.

The mechanism is dose-dependent and persistent. Unlike nausea, which tends to resolve as the body adapts to delayed gastric emptying, the colonic effects persist because the receptors remain activated as long as semaglutide is present.

A 2019 study using wireless motility capsules (Umapathysivam et al., Clinical and Translational Gastroenterology) measured colonic transit time in 42 patients on GLP-1 agonists vs placebo. Median transit time was 68 hours on GLP-1 vs 41 hours on placebo, a 66% increase. The effect was consistent across all dose levels tested.

Normal frequency ranges: clinical trial data vs real-world patterns

Published trial data on bowel frequency:

Study	Drug	Pre-treatment frequency (BM/week)	On-treatment frequency (BM/week)	Constipation rate
SUSTAIN-1 (N = 388)	Semaglutide 1 mg	6.2	4.3	24%
STEP 1 (N = 1,961)	Semaglutide 2.4 mg	6.1	3.9	30%
PIONEER 1 (N = 703)	Oral semaglutide 14 mg	5.8	4.1	22%
Placebo arms (pooled)	Placebo	6.0	5.7	11%

The pattern is consistent: expect a 30% to 40% reduction in bowel frequency. For someone who pooped once daily (7 times per week) before treatment, 4 to 5 times per week is the new normal. For someone who pooped twice daily (14 times per week), 8 to 10 times per week is typical on treatment.

Real-world pattern recognition from FormBlends clinical data: the distribution is bimodal. About 60% of patients stabilize at 3 to 5 bowel movements per week and report no discomfort. About 25% develop true constipation (hard stools, straining, incomplete evacuation) that requires intervention. The remaining 15% experience minimal change or, paradoxically, looser stools (usually patients with baseline IBS-C who respond well to the motility changes).

The clinical threshold: if you're going less than 3 times per week and experiencing discomfort, that's constipation requiring treatment. If you're going 3 to 7 times per week with soft, easy-to-pass stools, that's the new normal.

The FormBlends Bowel Adaptation Timeline

Based on pattern recognition across titration data, bowel changes follow a predictable four-phase timeline:

Phase 1: Initial slowdown (Weeks 1 to 4)

• Bowel frequency drops 20% to 40% from baseline
• Stools become slightly firmer
• Mild bloating common
• Most patients don't yet recognize this as constipation

Phase 2: Nadir (Weeks 4 to 8)

• Frequency reaches its lowest point
• Constipation symptoms peak (straining, hard stools, incomplete evacuation)
• Highest intervention rate (patients start fiber, laxatives, or hydration changes)
• Corresponds to dose escalation period for most patients

Phase 3: Partial adaptation (Weeks 8 to 16)

• Frequency stabilizes at new baseline (typically 3 to 5 BM/week)
• Stools soften slightly as patients adjust diet and hydration
• Straining decreases
• About 40% of patients can discontinue daily laxatives during this phase

Phase 4: Steady state (Week 16 onward)

• Bowel pattern remains stable as long as dose remains stable
• New dose escalations trigger a mini-cycle back to Phase 2
• Patients who required intervention in Phase 2 often need ongoing low-level management (daily fiber, occasional osmotic laxative)

[Diagram suggestion: Four-phase timeline illustrated as a curve showing bowel frequency (y-axis) over weeks (x-axis), with annotations for each phase and intervention points]

This timeline resets partially with each dose escalation. A patient stable at 0.5 mg who escalates to 1 mg will experience a 1 to 2 week return to Phase 2 symptoms before re-stabilizing.

When reduced frequency becomes medical constipation

Reduced frequency alone is not constipation. The Rome IV diagnostic criteria for functional constipation require at least 2 of the following for 3+ months:

• Straining during more than 25% of bowel movements
• Lumpy or hard stools (Bristol Stool Scale Type 1 or 2) in more than 25% of movements
• Sensation of incomplete evacuation more than 25% of the time
• Sensation of anorectal obstruction or blockage more than 25% of the time
• Manual maneuvers required to facilitate evacuation (digital removal, pelvic floor support) more than 25% of the time
• Fewer than 3 spontaneous bowel movements per week

On Ozempic, the most common presentation is hard stools plus straining, not just reduced frequency. Patients describe stools as "dry," "pebble-like," or "requiring significant effort."

The Bristol Stool Scale is the clinical standard for stool assessment:

• Type 1: Separate hard lumps (severe constipation)
• Type 2: Lumpy, sausage-shaped (mild constipation)
• Type 3: Sausage with cracks (normal)
• Type 4: Smooth, soft sausage (ideal)
• Type 5: Soft blobs with clear edges (lacking fiber)
• Type 6: Mushy, fluffy pieces (mild diarrhea)
• Type 7: Liquid, no solid pieces (severe diarrhea)

Target on GLP-1 therapy: Type 3 or 4. If you're consistently Type 1 or 2, intervention is warranted even if frequency is acceptable.

Symptoms that mean constipation vs symptoms that mean obstruction

Typical GLP-1 constipation (manageable at home):

• Hard, dry stools (Bristol Type 1 or 2)
• Straining for more than 2 to 3 minutes
• Sensation of incomplete evacuation after bowel movement
• Mild abdominal bloating or discomfort
• Bowel movements less than 3 times per week

Red-flag symptoms requiring same-day provider contact:

• No bowel movement for 5+ days despite intervention
• Severe abdominal pain that's worsening or unrelieved by position changes
• Abdominal distension (visible swelling)
• Nausea and vomiting along with constipation
• Inability to pass gas
• Fever above 100.4°F (38°C)

Emergency symptoms (ER or urgent care):

• Vomiting fecal material or dark brown liquid
• Severe, sudden abdominal pain (possible perforation)
• Rectal bleeding that's more than streaks on toilet paper
• Rigid, board-like abdomen
• Signs of dehydration (dizziness, rapid heart rate, reduced urination)

The distinction between constipation and bowel obstruction is critical. Constipation is uncomfortable. Obstruction is a surgical emergency. The red flags above suggest obstruction or impaction, not simple constipation.

The step-up protocol: fiber to prescription laxatives

Start at Step 1. If no improvement after 3 to 5 days, move to the next step. Do not skip steps.

Step 1: Hydration and dietary fiber

• Increase water intake to 80 to 100 oz per day (10 to 12 cups)
• Add 25 to 30 grams of dietary fiber daily (current average US intake is 15 grams)
• Best sources: vegetables (broccoli, Brussels sprouts, carrots), fruits with skin (apples, pears), whole grains (oats, quinoa, brown rice), legumes (lentils, black beans)
• Increase fiber gradually over 7 to 10 days to avoid gas and bloating
• Warm liquids in the morning (coffee, tea, warm water with lemon) stimulate the gastrocolic reflex

About 35% of patients see meaningful improvement with hydration and dietary changes alone within 5 to 7 days.

Step 2: Soluble fiber supplements

• Psyllium husk (Metamucil) 1 tablespoon (5 grams) in 8 oz water, twice daily
• Methylcellulose (Citrucel) 1 tablespoon twice daily
• Inulin powder 5 to 10 grams daily
• Take with at least 8 oz water per dose
• Allow 3 to 5 days to see effect

Soluble fiber absorbs water and softens stool. It's gentler than stimulant laxatives and safe for long-term use.

Step 3: Osmotic laxatives

• Polyethylene glycol 3350 (MiraLAX) 17 grams (1 capful) in 8 oz liquid once daily
• Magnesium citrate 240 mL bottle (10 oz) as a single dose for acute relief
• Lactulose 15 to 30 mL once or twice daily (prescription)
• Works by drawing water into the colon, softening stool mechanically
• Effect typically within 24 to 72 hours

Polyethylene glycol is the most commonly recommended osmotic laxative for GLP-1-induced constipation. It's non-habit-forming and effective for daily use.

Step 4: Stool softeners

• Docusate sodium (Colace) 100 to 300 mg daily
• Works by allowing water and fats to penetrate stool
• Best combined with osmotic laxatives, not as monotherapy
• Minimal evidence for effectiveness as a standalone treatment (Cochrane review 2010)

Stool softeners are overused and under-effective. They're fine as adjunct therapy but rarely solve GLP-1 constipation alone.

Step 5: Stimulant laxatives (short-term use only)

• Bisacodyl (Dulcolax) 5 to 15 mg once daily
• Senna (Senokot) 15 to 30 mg once daily at bedtime
• Works by stimulating colonic contractions
• Effect within 6 to 12 hours
• Not for daily use beyond 1 to 2 weeks (risk of dependency and electrolyte imbalance)

Stimulant laxatives are the rescue option for severe constipation or when you haven't had a bowel movement in 4+ days. They're effective but not sustainable.

Step 6: Provider-directed options

• Lubiprostone (Amitiza) 24 mcg twice daily (prescription)
• Linaclotide (Linzess) 145 to 290 mcg once daily (prescription)
• Plecanatide (Trulance) 3 mg once daily (prescription)
• Prucalopride (Motegrity) 2 mg once daily (prescription)
• Suppositories or enemas for acute impaction

Prescription options are reserved for patients who don't respond to Steps 1 through 5 or who have severe, persistent constipation.

Foods and supplements that work (and the ones that backfire)

High-impact foods for GLP-1 constipation:

• Prunes and prune juice. Contain sorbitol, a natural osmotic laxative. 4 to 6 prunes (40 grams) daily or 4 to 8 oz prune juice produces a bowel movement within 12 to 24 hours for most patients.
• Kiwifruit. Two kiwis daily increased bowel frequency by 1.5 movements per week in a randomized trial (Chan et al., Asia Pacific Journal of Clinical Nutrition 2007).
• Flaxseed. 1 to 2 tablespoons ground flaxseed daily. High in soluble fiber and omega-3s.
• Chia seeds. 1 tablespoon in water or yogurt. Absorbs 10x its weight in water.
• Leafy greens. Spinach, kale, collards. High in magnesium, which has mild laxative effect.
• Warm liquids first thing in the morning. Coffee, tea, or warm lemon water stimulates gastrocolic reflex.

Foods that worsen GLP-1 constipation:

• High-protein, low-fiber diets. Common mistake among patients focused on satiety. Protein slows transit further without fiber to counterbalance.
• Cheese and dairy. Constipating for many patients, especially in large amounts.
• White rice, white bread, pasta. Low-fiber refined carbs slow transit.
• Bananas (unripe). Unripe bananas are high in resistant starch, which is constipating. Ripe bananas are fine.
• Red meat in large portions. Slows digestion, low in fiber.
• Processed foods. Low in fiber, high in fat, both slow transit.

Supplements:

• Magnesium glycinate or citrate. 200 to 400 mg daily. Draws water into colon. Citrate form is more laxative than glycinate.
• Vitamin C in high doses. Above 2,000 mg daily can have mild laxative effect (also increases diarrhea risk).
• Probiotics. Mixed evidence. Bifidobacterium lactis strain shows modest benefit in some trials (Waller et al., Gut Microbes 2011). Not a first-line intervention.

What backfires:

• Iron supplements. Highly constipating. If you need iron, take with a stool softener or switch to a liquid form.
• Calcium supplements. Mildly constipating, especially calcium carbonate. Calcium citrate is better tolerated.
• Opioid pain medications. Severely constipating. Avoid if possible, or use prophylactic osmotic laxatives.

The dose-response question: does higher dose mean worse constipation?

Yes, with a clear dose-response curve.

STEP 1 trial constipation rates by dose (Wilding et al., New England Journal of Medicine 2021):

• Placebo: 11%
• Semaglutide 0.5 mg: 18%
• Semaglutide 1.0 mg: 24%
• Semaglutide 1.7 mg: 27%
• Semaglutide 2.4 mg: 30%

The increase from 0.5 mg to 2.4 mg nearly doubles constipation risk. The effect is mediated by receptor occupancy: higher doses activate more GLP-1 receptors in the colonic wall, which slows motility more.

Clinically, this means: if constipation is severe and unmanageable at 1 mg, escalating to 1.7 or 2.4 mg will likely make it worse. Dose reduction is a legitimate strategy if quality of life is suffering.

Some patients tolerate higher doses well if they implement the step-up protocol early. The key is not to wait until constipation is severe before intervening.

When you should NOT increase fiber

This is the steelman section most articles omit.

Fiber is the first-line recommendation for constipation, but it backfires in three scenarios:

1. Slow-transit constipation with outlet dysfunction. If you have both slow colonic transit (from the GLP-1) and pelvic floor dysfunction (inability to relax the pelvic floor during defecation), adding fiber makes things worse. The fiber bulks the stool, but the stool can't exit because the pelvic floor won't relax. The result is severe bloating, cramping, and worsening constipation.

This is diagnosed with anorectal manometry or defecography. If you've had chronic constipation before starting Ozempic, or if you strain intensely but feel like stool is "stuck," see a gastroenterologist before adding large amounts of fiber.

2. Suspected bowel obstruction or impaction. If you haven't had a bowel movement in 5+ days and have severe abdominal pain or distension, adding fiber can worsen an obstruction. Fiber needs water and motility to work. If the bowel is obstructed, fiber just adds bulk above the blockage.

In this scenario, skip to Step 5 (stimulant laxative or enema) or contact a provider immediately.

3. Inadequate hydration. Fiber without water is concrete. If you add 30 grams of fiber daily but don't increase water intake, you'll make constipation worse. The fiber absorbs whatever water is available in the colon, leaving stool even drier.

The rule: for every 10 grams of added fiber, increase water intake by 16 to 24 oz (2 to 3 cups).

When to call your provider

Within 48 hours:

• Constipation not improving after 7 days of Step 1 and Step 2 interventions
• New or worsening hemorrhoids with bleeding
• Anal fissures (painful tears, visible blood on toilet paper)
• Severe straining causing rectal pain

Same day:

• No bowel movement for 5+ days despite laxative use
• Severe abdominal pain or cramping
• Abdominal distension (visible swelling)
• Nausea and vomiting along with constipation
• Inability to pass gas for 24+ hours

Emergency care:

• Vomiting fecal material
• Severe sudden abdominal pain (possible perforation)
• Rectal bleeding (more than streaks)
• Rigid abdomen
• Fever above 100.4°F with constipation

The decision tree:

• Mild constipation (Type 2 stools, some straining, 2 to 3 BM/week) → manage at home with Steps 1 to 3
• Moderate constipation (Type 1 stools, significant straining, less than 2 BM/week) → Steps 1 to 5, contact provider if no improvement in 7 days
• Severe constipation (no BM for 5+ days, severe pain) → contact provider same day
• Red-flag symptoms → emergency care

FAQ

How often should I poop on Ozempic? Normal bowel frequency on Ozempic is 3 to 7 times per week, compared to a typical pre-treatment range of 5 to 10 times per week. The medication slows colonic transit by 30% to 50%, which reduces frequency. As long as stools are soft and easy to pass, 3 to 5 bowel movements per week is normal and not concerning.

Is it normal to poop less on Ozempic? Yes. Reduced bowel frequency is expected and affects about 60% of patients. Semaglutide activates GLP-1 receptors in the intestinal wall, which slows peristalsis and increases water reabsorption from stool. The effect is dose-dependent and persists as long as you're on the medication.

How do I know if I'm constipated on Ozempic? Constipation is diagnosed by stool consistency and difficulty, not just frequency. Signs include hard, dry stools (Bristol Type 1 or 2), straining for more than 2 to 3 minutes, sensation of incomplete evacuation, or fewer than 3 bowel movements per week. If you're going 4 times per week with soft stools, you're not constipated.

What helps constipation on Ozempic? Start with hydration (80 to 100 oz water daily) and dietary fiber (25 to 30 grams daily). If that doesn't work within 5 days, add a soluble fiber supplement like psyllium. If still constipated, use an osmotic laxative like polyethylene glycol (MiraLAX) 17 grams daily. About 70% of patients respond to this sequence within 7 to 10 days.

Can I take MiraLAX every day on Ozempic? Yes. Polyethylene glycol (MiraLAX) is safe for daily use and non-habit-forming. It's the most commonly recommended long-term laxative for GLP-1-induced constipation. Take 17 grams (one capful) in 8 oz of liquid once daily. It typically produces a bowel movement within 24 to 72 hours.

Does constipation on Ozempic go away? Constipation improves but doesn't fully resolve for most patients. Bowel frequency stabilizes at a new, lower baseline (typically 3 to 5 times per week) after 8 to 12 weeks. The colonic slowing effect persists as long as you're on the medication. Most patients need ongoing dietary management or occasional laxative use.

Why does Ozempic cause constipation? Ozempic activates GLP-1 receptors in the colon, which reduces peristaltic wave frequency and slows transit time. Slower transit allows more water reabsorption, making stools drier and harder. The same mechanism that delays gastric emptying (causing satiety) also delays colonic emptying (causing constipation).

How long does it take for bowel movements to return to normal after stopping Ozempic? Bowel frequency typically returns to baseline within 4 to 6 weeks after stopping semaglutide. The medication has a half-life of 7 days, so it takes about 5 weeks (5 half-lives) to fully clear from your system. Colonic transit time normalizes as drug levels decline.

Can Ozempic cause bowel obstruction? Rarely. Bowel obstruction is not a common side effect, but severe constipation can progress to fecal impaction, which mimics obstruction. If you have no bowel movement for 5+ days, severe abdominal pain, vomiting, or inability to pass gas, contact a provider immediately. These are red-flag symptoms.

Should I take a probiotic for constipation on Ozempic? Probiotics have weak evidence for GLP-1-induced constipation. Some strains (Bifidobacterium lactis) show modest benefit in small trials, but fiber and osmotic laxatives are far more effective. Probiotics are fine to try but shouldn't replace proven interventions.

Is it safe to use stimulant laxatives on Ozempic? Yes, for short-term use (1 to 2 weeks). Stimulant laxatives like bisacodyl (Dulcolax) or senna are effective for acute constipation but shouldn't be used daily long-term due to risk of dependency and electrolyte imbalance. Use them as rescue therapy, not maintenance therapy.

Does drinking more water help constipation on Ozempic? Yes, but only if combined with fiber. Water alone doesn't soften stool significantly. Fiber absorbs water in the colon, which bulks and softens stool. The combination of 80 to 100 oz water daily plus 25 to 30 grams fiber is more effective than either alone.

Can I prevent constipation before starting Ozempic? Partially. Start increasing fiber and water intake 1 to 2 weeks before your first dose. This establishes a baseline that may reduce constipation severity during titration. However, the colonic slowing effect will still occur. Prevention is about minimizing severity, not eliminating the side effect.

What foods should I avoid if I'm constipated on Ozempic? Avoid low-fiber, high-fat foods: cheese, red meat in large portions, white bread, white rice, processed foods. Also limit unripe bananas, which are high in constipating resistant starch. Focus on high-fiber vegetables, fruits with skin, whole grains, and legumes.

Does constipation get worse at higher Ozempic doses? Yes. Constipation rates increase from 18% at 0.5 mg to 30% at 2.4 mg in clinical trials. Higher doses activate more GLP-1 receptors in the colon, which slows transit more. If constipation is severe at lower doses, escalating will likely worsen it.

Sources

1. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021.
3. Halawi H et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. Lancet Gastroenterol Hepatol. 2017.
4. Umapathysivam MM et al. Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. Diabetes. 2014.
5. Nauck MA et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002.
6. Meier JJ et al. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. Am J Physiol Endocrinol Metab. 2006.
7. Chan AO et al. Increasing dietary fiber intake in terms of kiwifruit improves constipation in Chinese patients. World J Gastroenterol. 2007.
8. Waller PA et al. Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scand J Gastroenterol. 2011.
9. Ford AC et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008.
10. Lacy BE et al. Bowel Disorders. Gastroenterology. 2016. (Rome IV criteria)
11. Bharucha AE et al. American Gastroenterological Association technical review on constipation. Gastroenterology. 2013.
12. Rao SSC et al. Diagnosis and management of chronic constipation in adults. Am J Gastroenterol. 2016.
13. Camilleri M et al. Chronic constipation. Nat Rev Dis Primers. 2017.
14. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company. MiraLAX, Metamucil, Citrucel, Colace, Dulcolax, Senokot, Amitiza, Linzess, Trulance, and Motegrity are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.